Chris Mead. Wondrous Strange: Seven Brief Thoughts on New Plays: Sydney: Currency Press, 2022. 176 pages. AU$29.99. ISBN: 9781760627539 (Paperback)

Stephen Carleton reviews, Chris Mead's, Wondrous Strange: Seven Brief Thoughts on New Plays (2022)

Contemporary Irish gothic drama: The return of the Hibernian repressed during the rise and fall of the Celtic tiger

Whilst debate rages in certain circles as to what constitutes an Irish Gothic tradition and whether imposing canonical status upon it is even possible or desirable, very little of this discussion focuses on twenty-first century writing, and certainly not upon writing for the stage. The aims of this essay are twofold: to argue the case for a contemporary Irish Gothic theatre' school' (whose primary proponents I will identify as Martin McDonagh, Conor McPherson, Marina Carr and Mark O'Rowe); and to place this contemporary' school' in conversation with the Irish Gothic literary corpus identified by the scholarship of Terry Eagleton, Seamus Deane, W. J. McCormack, Jarlath Killeen, Christopher Morash, Richard Haslam, Sinéad Mooney and David Punter. The resulting intention here is to open up a fresh way of reading and comparing contemporary Irish playwrights that allows us to place their work into sharper focus when it comes to comparing them to each other as pre-eminent Irish writers of the millennial period

The Turquoise Elephant

Second production of 'The Turquoise Elephant'; Darwin, NT. Inside her triple-glazed compound, Augusta shields herself from the catastrophic elements, bathing in the classics and campaigning for the reinstatement of global reliance on fossil fuels. Outside, the world lurches from one environmental cataclysm to the next. Meanwhile, her sister, Olympia, thinks the best way to save endangered species is to eat them. Their niece, Basra, is intent on making a difference–but how? Can you save the world one blog at a time? Stephen Carleton’s shockingly black, black, black political farce won the 2015 Griffin Award. It’s urgent, contemporary and perilously close to being real

The Cultural Atlas of Australia

An online interactive map and associated database including textual extracts and audiovisual material of film/novel/play locations in Australia

Developmental arrest of T cells in RpL22-deficient mice is dependent upon multiple p53 effectors

available in PMC 2012 July 15alpha beta and gamma delta lineage T cells are thought to arise from a common CD4–CD8– progenitor in the thymus. However, the molecular pathways controlling fate selection and maturation of these two lineages remain poorly understood. We demonstrated recently that a ubiquitously expressed ribosomal protein, Rpl22, is selectively required for the development of alpha beta lineage T cells. Germline ablation of Rpl22 impairs development of alpha beta lineage, but not gamma delta lineage, T cells through activation of a p53-dependent checkpoint. In this study, we investigate the downstream effectors used by p53 to impair T cell development. We found that many p53 targets were induced in Rpl22−/− thymocytes, including miR-34a, PUMA, p21waf, Bax, and Noxa. Notably, the proapoptotic factor Bim, while not a direct p53 target, was also strongly induced in Rpl22−/− T cells. Gain-of-function analysis indicated that overexpression of miR-34a caused a developmental arrest reminiscent of that induced by p53 in Rpl22-deficient T cells; however, only a few p53 targets alleviated developmental arrest when individually ablated by gene targeting or knockdown. Co-elimination of PUMA and Bim resulted in a nearly complete restoration of development of Rpl22−/− thymocytes, indicating that p53-mediated arrest is enforced principally through effects on cell survival. Surprisingly, co-elimination of the primary p53 regulators of cell cycle arrest (p21waf) and apoptosis (PUMA) actually abrogated the partial rescue caused by loss of PUMA alone, suggesting that the G1 checkpoint protein p21[superscript waf] facilitates thymocyte development in some contexts.National Institutes of Health (U.S.) ( (NIH) Grant R01AI073920)National Institutes of Health (U.S.) (NIH Core Grant P01CA06927)National Institutes of Health (U.S.) ( (NIH) Grant R21CA141194)National Institutes of Health (U.S.) ( NIH Center Grant P30-DK-50306)Pennsylvania (appropriation)Fox Chase Cancer Center (NIH Postdoctoral Training Grant T32 CA00903534)Fox Chase Cancer Center (NIH Postdoctoral Training Grant F32 AI089077-01A1

A Long-term Co-perfused Disseminated Tuberculosis-3D Liver Hollow Fiber Model for Both Drug Efficacy and Hepatotoxicity in Babies

AbstractTreatment of disseminated tuberculosis in children≤6years has not been optimized. The pyrazinamide-containing combination regimen used to treat disseminated tuberculosis in babies and toddlers was extrapolated from adult pulmonary tuberculosis. Due to hepatotoxicity worries, there are no dose–response studies in children. We designed a hollow fiber system model of disseminated intracellular tuberculosis with co-perfused three-dimensional organotypic liver modules to simultaneously test for efficacy and toxicity. We utilized pediatric pharmacokinetics of pyrazinamide and acetaminophen to determine dose-dependent pyrazinamide efficacy and hepatotoxicity. Acetaminophen concentrations that cause hepatotoxicity in children led to elevated liver function tests, while 100mg/kg pyrazinamide did not. Surprisingly, pyrazinamide did not kill intracellular Mycobacterium tuberculosis up to fourfold the standard dose as monotherapy or as combination therapy, despite achieving high intracellular concentrations. Host-pathogen RNA-sequencing revealed lack of a pyrazinamide exposure transcript signature in intracellular bacteria or of phagolysosome acidification on pH imaging. Artificial intelligence algorithms confirmed that pyrazinamide was not predictive of good clinical outcomes in children≤6years who had extrapulmonary tuberculosis. Thus, adding a drug that works inside macrophages could benefit children with disseminated tuberculosis. Our in vitro model can be used to identify such new regimens that could accelerate cure while minimizing toxicity

National Computational Infrastructure for Lattice Gauge Theory SciDAC-2 Closeout Report

Under its SciDAC-1 and SciDAC-2 grants, the USQCD Collaboration developed software and algorithmic infrastructure for the numerical study of lattice gauge theories

A Canadian Study of Cisplatin Metabolomics and Nephrotoxicity (ACCENT): A Clinical Research Protocol

Background: Cisplatin, a chemotherapy used to treat solid tumors, causes acute kidney injury (AKI), a known risk factor for chronic kidney disease and mortality. AKI diagnosis relies on biomarkers which are only measurable after kidney damage has occurred and functional impairment is apparent; this prevents timely AKI diagnosis and treatment. Metabolomics seeks to identify metabolite patterns involved in cell tissue metabolism related to disease or patient factors. The A Canadian study of Cisplatin mEtabolomics and NephroToxicity (ACCENT) team was established to harness the power of metabolomics to identify novel biomarkers that predict risk and discriminate for presence of cisplatin nephrotoxicity, so that early intervention strategies to mitigate onset and severity of AKI can be implemented. Objective: Describe the design and methods of the ACCENT study which aims to identify and validate metabolomic profiles in urine and serum associated with risk for cisplatin-mediated nephrotoxicity in children and adults. Design: Observational prospective cohort study. Setting: Six Canadian oncology centers (3 pediatric, 1 adult and 2 both). Patients: Three hundred adults and 300 children planned to receive cisplatin therapy. Measurements: During two cisplatin infusion cycles, serum and urine will be measured for creatinine and electrolytes to ascertain AKI. Many patient and disease variables will be collected prospectively at baseline and throughout therapy. Metabolomic analyses of serum and urine will be done using mass spectrometry. An untargeted metabolomics approach will be used to analyze serum and urine samples before and after cisplatin infusions to identify candidate biomarkers of cisplatin AKI. Candidate metabolites will be validated using an independent cohort. Methods: Patients will be recruited before their first cycle of cisplatin. Blood and urine will be collected at specified time points before and after cisplatin during the first infusion and an infusion later during cancer treatment. The primary outcome is AKI, defined using a traditional serum creatinine-based definition and an electrolyte abnormality-based definition. Chart review 3 months after cisplatin therapy end will be conducted to document kidney health and survival. Limitations: It may not be possible to adjust for all measured and unmeasured confounders when evaluating prediction of AKI using metabolite profiles. Collection of data across multiple sites will be a challenge. Conclusions: ACCENT is the largest study of children and adults treated with cisplatin and aims to reimagine the current model for AKI diagnoses using metabolomics. The identification of biomarkers predicting and detecting AKI in children and adults treated with cisplatin can greatly inform future clinical investigations and practices